<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097343</url>
  </required_header>
  <id_info>
    <org_study_id>09-2104</org_study_id>
    <nct_id>NCT01097343</nct_id>
  </id_info>
  <brief_title>Clopidogrel Pharmacogenomics Project</brief_title>
  <official_title>Clopidogrel Pharmacogenomics Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <brief_summary>
    <textblock>
      Loss-of-function mutation of the gene encoding the CYP450 2C19 enzyme has emerged as a likely
      determinant of resistance to clopidogrel therapy. The primary hypothesis of the proposed
      research is that among patients with confirmed loss-of-function alleles of the CYP2C19 gene,
      increasing the maintenance clopidogrel dose from 75 to 150 mg will result in significant
      reduction in the rate of measured clopidogrel resistance defined by multiple measures of
      platelet function
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first phase of the clinical trial will involve subject recruitment and informed consent
      for genetic testing. Because the target population is patients with stable coronary artery
      disease, patients will be recruited from the outpatient setting during clinic visits or at
      the time of outpatient cardiac catheterization. It is expected that all potential candidates
      will be initially screened for eligibility by their treating cardiologist. If a patient
      agrees to undergo formal screening, they will be approached by a member of the research team
      and receive a written summary of the clinical trial protocol that will be reviewed with the
      trial personnel. The initial informed consent will allow the patient to undergo genetic
      testing and baseline VerifyNow assay, and will also give the trial personnel permission to
      contact the patient by phone if they are found to be eligible for the interventional phase of
      the trial. The goal for enrollment in the genetic testing portion of this clinical trial is
      200 patients.

      If the genetic testing results confirm that the patient is a candidate for the interventional
      study, they will be contacted and asked to make an outpatient appointment to initiate the
      interventional study protocol. The therapeutic portion of this study will be a randomized,
      unblinded cross-over comparison of two clopidogrel dosing strategies. It is anticipated that
      all eligible patients will have continued their previous chronic clopidogrel therapy with
      standard dosing of 75 mg/day. Because all patients will be receiving chronic clopidogrel at
      the initiation of the intervention protocol, steady state levels should be present in all
      patients. Dose dependent inhibition of platelet aggregation can be seen two hours after a
      single oral dose of clopidogrel. Repeated doses of 75mg daily produce steady state inhibition
      between day 3 and day 7 of administration.

      Patients who agree to participate in the therapeutic protocol, and who meet the eligibility
      criteria, will be randomized to an initial dosing strategy of 75 or 150 mg daily for a
      minimum of 30 days. At day 30 (+/- 5 days), patients will return for repeat platelet function
      testing. In a randomly selected subset of 15 patients, blood will be tested for the active
      metabolite of clopidogrel. At that time, there will be a crossover with those patients
      receiving 75 mg qD increased to 150 mg qD and those receiving 150 mg qD decreased to 75 mg
      qD. At day 60 (+/- 5 days), participants will again return for comprehensive platelet
      function testing and a second randomly selected group of patients will undergo testing for
      clopidogrel metabolites. Chronic clopidogrel dosing will be reduced to 75mg in all
      participants. Please see the attached schedule of events for a summary of the trial schedule.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clopidogrel Resistance, Defined by P2Y12 Reaction Units (PRU)Value &gt;230</measure>
    <time_frame>Approximately 90 days</time_frame>
    <description>P2Y12 Reaction Units are measured using the VerifyNow P2Y12 assay. Percent of patients with clopidogrel resistance defined by PRU value will be compared among low and high dose clopidogrel groups after 30 days of therapy.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Disease Susceptibility</condition>
  <arm_group>
    <arm_group_label>75 mg clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel 75 mg</intervention_name>
    <description>75 mg once daily</description>
    <arm_group_label>75 mg clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 150 mg</intervention_name>
    <description>clopidogrel 150 mg</description>
    <arm_group_label>150 mg clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:• Currently taking clopidogrel 75 mg/day and aspirin (minimum 81 mg/day)
        with an indication for chronic dual antiplatelet therapy (&gt;90 days)

          -  No evidence of acute coronary syndrome within 30 days of enrollment, defined by
             elevation of Troponin I above the upper limit of normal

          -  Coronary atherosclerosis documented on previous coronary angiogram

          -  No known contraindications to combination therapy with aspirin and clopidogrel

          -  Prognosis for survival greater than one year based on physician's assessment

          -  Able to attend all scheduled visits.

          -  Access to phone

          -  Subject is a female with a negative urine or serum pregnancy test or post-menopausal
             for at least 1 year prior to randomization. Females of childbearing potential must be
             practicing adequate birth control to be eligible. It is the Investigator's
             responsibility for determining whether the Subject has adequate birth control for
             study participation

        Exclusion Criteria:• Recent acute coronary syndrome (&lt;30 days)

          -  Recent hospitalization or physician visit for bleeding disorder(&lt;90 days) or history
             of chronic blood loss

          -  Recent blood transfusion (&lt;90 days)

          -  Any contraindication to aspirin or clopidogrel therapy

          -  Acute Febrile illness at the time of enrollment

          -  Subject is pregnant or lactating or planning to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Rossi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2010</study_first_posted>
  <results_first_submitted>July 9, 2012</results_first_submitted>
  <results_first_submitted_qc>February 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2014</results_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clopidogrel pharmacogenomics study</keyword>
  <keyword>Performing genetic study looking at clopidogrel resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>50 patients with 2C19*2 polymorphism were recruited to participate in a cross-over study comparing 75 vs. 150 mg of clopidogrel. 25 patients were randomized to start with 75 mg, and 25 patients started with 150 mg for 30 day dosing periods.</recruitment_details>
      <pre_assignment_details>Cross-over study with two 30-day dosing periods. All patients were receiving chronic clopidogrel prior to enrollment after percutaneous coronary intervention.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>75 mg First 30 Days, Followed by 150 mg</title>
          <description>25 patients with the target allele were identified, and receive 75mg followed by 150 mg clopidogrel daily for two separate dosing periods of 30 days</description>
        </group>
        <group group_id="P2">
          <title>150 mg First 30 Days, Followed by 75 mg</title>
          <description>25 patients with the target allele were identified, and received 150 mg clopidogrel followed by 75 mg clopidogrel for two daily for separate dosing periods of 30 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention- 30 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention- 30 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cross-over Study</title>
          <description>All Study Participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.8" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clopidogrel Resistance, Defined by P2Y12 Reaction Units (PRU)Value &gt;230</title>
        <description>P2Y12 Reaction Units are measured using the VerifyNow P2Y12 assay. Percent of patients with clopidogrel resistance defined by PRU value will be compared among low and high dose clopidogrel groups after 30 days of therapy.</description>
        <time_frame>Approximately 90 days</time_frame>
        <population>All patients completed the clinical protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Cross-over Study- 75 mg Dose</title>
            <description>Participants received standard dose clopidogrel (75 mg) and higher dose (150 mg) for 30 days</description>
          </group>
          <group group_id="O2">
            <title>Cross-over Study - 150 mg Dose</title>
            <description>Participants received standard dose clopidogrel (75 mg) and higher dose (150 mg) for 30 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clopidogrel Resistance, Defined by P2Y12 Reaction Units (PRU)Value &gt;230</title>
          <description>P2Y12 Reaction Units are measured using the VerifyNow P2Y12 assay. Percent of patients with clopidogrel resistance defined by PRU value will be compared among low and high dose clopidogrel groups after 30 days of therapy.</description>
          <population>All patients completed the clinical protocol.</population>
          <units>Number of Patients with PRU&gt;230</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A sample of size of 50 patients for the cross-over study was chosen because it provided 80% power to detect a decrease in the rate of high on-clopidogrel platelet reactivity (HPR, defined as &gt;230 PRU) from 75% to 46% with high dose clopidogrel, with a two-sided alpha of 0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.02</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for 90 days after enrollment in the dosing study.</time_frame>
      <desc>Adverse event data was collected during patient visits and with a follow-up phone call 30 days after completion of the dosing protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>75 mg Followed by 150 mg</title>
          <description>Cross-over study</description>
        </group>
        <group group_id="E2">
          <title>150 mg Followed by 75 mg</title>
          <description>Cross-over study</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Major Bleeding</sub_title>
                <description>GI bleeding requiring blood transfusion- this event occurred in a patient receiving the 150mg dose</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joseph S. Rossi</name_or_title>
      <organization>St. Vincent Medical Group</organization>
      <phone>765 482 0656</phone>
      <email>jrossi@thecaregroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

